SAREPTA THERAPEUTICS
Sarepta Therapeutics is a biopharmaceutical company that focuses on the discovery and development of precision genetic medicine to treat rare diseases. It specializes in gene therapy, RNA-targeted exon skipping, and gene editing. It was founded in 1980 and headquartered in Cambridge, Massachusetts.
SAREPTA THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
1980-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.sarepta.com
Total Employee:
501+
Status:
Active
Contact:
5417543545
Email Addresses:
[email protected]
Total Funding:
1.38 B USD
Technology used in webpage:
SPF Domain Not Resolving Amazon Microsoft Azure DNS Amazon Virginia Region DMARC Mimecast ASP.NET 2.0 Symantec.cloud EasyDNS
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Corvidia
Corvidia Therapeutics focuses on the research and development of transformative therapies for cardio-renal diseases.
Horizon Pharma
Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-02-27 | Myonexus Therapeutics | Myonexus Therapeutics acquired by Sarepta Therapeutics | 165 M USD |
| 2014-07-07 | Eisai | Eisai acquired by Sarepta Therapeutics | 25 M USD |
| 2008-03-12 | Ercole Biotech | Ercole Biotech acquired by Sarepta Therapeutics | N/A |
Investors List
Roche Financial
Roche Financial investment in Post-IPO Equity - Sarepta Therapeutics
Pharmakon Advisors
Pharmakon Advisors investment in Post-IPO Debt - Sarepta Therapeutics
MidCap Financial
MidCap Financial investment in Post-IPO Debt - Sarepta Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-03-16 | StrideBio | Sarepta Therapeutics investment in Series B - StrideBio | 81.5 M USD |
| 2020-10-22 | AavantiBio | Sarepta Therapeutics investment in Series A - AavantiBio | 107 M USD |
| 2018-08-09 | Lacerta Therapeutics | Sarepta Therapeutics investment in Venture Round - Lacerta Therapeutics | 30 M USD |
| 2018-05-08 | Myonexus Therapeutics | Sarepta Therapeutics investment in Corporate Round - Myonexus Therapeutics | 60 M USD |
Official Site Inspections
http://www.sarepta.com Semrush global rank: 1.15 M Semrush visits lastest month: 27.55 K
- Host name: ec2-54-204-43-126.compute-1.amazonaws.com
- IP address: 54.204.43.126
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Sarepta Therapeutics"
Meet Our Leadership | Sarepta Therapeutics
At Sarepta, I have found that every voice matters, respect matters and building trust matters – all of these contribute to an organization that is poised to transform the lives of patients. I cannot …See details»
Corporate Responsibility | Sarepta Therapeutics
At Sarepta, we strive to foster an environment where everyone can thrive. Workplace Demographics. Our employee demographics are included below, which reflect our commitment to building a culture that is inclusive and …See details»
Sarepta Therapeutics - Wikipedia
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drug…See details»
Arrowhead Pharmaceuticals Announces Global License and …
6 days ago Sarepta would then receive an exclusive license to those programs and be responsible for clinical development and commercialization. Drug Manufacturing Under the …See details»
Sarepta Therapeutics - LinkedIn
Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a global biotechnology company on an urgent mission: engineer precision genetic medicine for rare diseases that …See details»
Sarepta Therapeutics - Crunchbase Company Profile
Sarepta Therapeutics develops gene therapies aimed at treating Duchenne muscular dystrophy by delivering functional copies of the dystrophin gene to muscle cells. RNA-targeted Exon Skipping Sarepta's RNA technologies focus …See details»
Sarepta Therapeutics | Biopharmaceutical Company for …
Sarepta is engineering solutions for rare diseases with science that is on the forefront of precision genetic medicine. Our platforms include: gene therapy, RNA technologies, and gene editing. We are in a daily race to save lives stolen or …See details»
Sarepta Therapeutics Announces Global Licensing and …
5 days ago Sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system (CNS), and the lungs. ...See details»
Investor Relations | Sarepta Therapeutics, Inc.
At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. We hold leadership positions …See details»
Sarepta, Arrowhead ink $1B-plus deal for seven programs
5 days ago Sarepta’s equity investment in Arrowhead’s common stock represents a 35% premium to the biotech’s 30-day volume weighted average price, according to a Nov. 26 release. Over the span of five ...See details»
About Our Company - Sarepta Therapeutics
Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We’re ushering in a new …See details»
A Comprehensive Look at Sarepta's Growth and Innovation
Mar 25, 2024 Sarepta's revenue for the fourth quarter of 2023 was $396.80 million, exceeding our expectations by about $21.80 million and, just as importantly, up 53.50% year over year.See details»
Sarepta Therapeutics Named One of The Boston Globe’s Top …
Nov 20, 2020 -- Sarepta is honored to be recognized for offering a range of benefits and work-life resources to employees and supporting the local community---- Rankings based on …See details»
Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline
5 days ago The collaboration with Arrowhead is the first significant investment Sarepta has made to expand its pipeline in recent years. In a note to investors, Jefferies analyst Andrew …See details»
Sarepta Therapeutics Announces Global Licensing and …
5 days ago He has led Sarepta as they advanced multiple investigational medicines through the clinical and regulatory process, built a commercial organization from the ground up, launched …See details»
Sarepta to pay Arrowhead $500M - Nasdaq
5 days ago Sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system …See details»
The Science Behind Our Precision Genetic Medicine Platforms
Sarepta is pursuing the development of precision genetic medicine at the forefront of biotechnology for rare diseases: gene therapy, RNA-targeted exon skipping, and gene editing. …See details»
Sarepta ‘secures future’ with massive Arrowhead collaboration
6 days ago In the largest collaboration of 2024, Sarepta Therapeutics Inc. and Arrowhead Pharmaceuticals Inc. entered a sprawling global licensing deal that includes a swath of clinical …See details»
Arrowhead to get $825M in Sarepta licensing pact, appoints
5 days ago Arrowhead (ARWR) announced a global licensing and collaboration agreement with Sarepta (SRPT). Upon closing, Arrowhead will receive $825M, consisting of $500M cash and …See details»
Arrowhead to get $825M in Sarepta licensing pact, appoints …
5 days ago Arrowhead (ARWR) announced a global licensing and collaboration agreement with Sarepta (SRPT). Upon closing, Arrowhead will receive $825M, consisting of $500M cash and …See details»